You just don't get it, TTNP drug doesn't work at it's current formulation. New formulation needed, perhaps a few drops of Garlic Juice will make it more potent.
Now that will involve additional Clinical Trials and additional $$ funding.TTNP don't have much cash.
An Alternative Reading Of FDA Briefing Materials On Titan's Probuphine
Mar 20 2013, 08:13 | about: TTNP.OB
Most Titan Pharmaceuticals (TTNP.OB) investors did not expect the 40% drop in share price on the release of the briefing materials in advance of Thursday's FDA Psychopharmacologic Drugs Advisory Committee (PDAC) meeting. There is always a great deal of risk in biotech investing, especially when you are holding a position going into a big FDA decision. That is definitely the case as Titan approaches crucial votes on safety, efficacy, and application approval in the PDAC meeting on Thursday.
But why such a strong drop on the briefing materials, just two days before that vote?
If anything, investors like me expected the share price to be closer to $2.50 by Thursday as expressed in my recent background article on Titan. And with a high of $2.18 recorded on Monday, it was headed in that direction until the press reporting on the FDA document release.
Instead of continued optimistic expectation for Titan's committee votes on Thursday, what investors woke up to yesterday morning were the following headlines:
-Titan s Probuphine Dosing May Need New Review, FDA Says
-FDA Reviewers Say Titan s Drug Results Not as Strong as Hoped
These headlines are very misleading and do not accurately reflect the full extent of the FDA's summary comments and Titan's clinical results. Upon a full review of the briefing materials on which these articles were based, investors who sold may be very sorry come Thursday and miss gains as the PDAC votes on Probuphine.
Why The Press Analysis of Today's Briefing Material Is Misleading
The thrust of the press reports focused on language in the report that questioned the dosing strength (efficacy) of Probuphine and the safety of Probuphine.